Juthani Ronit, Manne Ashish
Department of Medicine, Saint Vincent Hospital, Worcester, MA, United States.
Department of Internal Medicine, Division of Medical Oncology at the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Comprehensive Cancer Center, Columbus, OH, United States.
Front Oncol. 2025 Apr 22;15:1555963. doi: 10.3389/fonc.2025.1555963. eCollection 2025.
Pancreatic Ductal Adenocarcinoma (PDAC) accounts for a significant burden of global cancer deaths worldwide. The dismal outcomes associated with PDAC can be overcome by detecting the disease early and developing tools that predict response to treatment, allowing the selection of the most optimal treatment. Over the last couple of years, significant progress has been made in the development of novel biomarkers that aid in diagnosis, prognosis, treatment selection, and monitoring response. Blood-based biomarkers offer an alternative to tissue-based diagnosis and offer immense potential in managing PDAC. In this review, we have discussed the advances in blood-based biomarkers in PDAC, such as DNA (mutations and methylations), RNA, protein biomarkers and circulating tumor cells (CTC) over the last decade and also elucidated all aspects of practical implementation of these biomarkers in clinical practice. We have also discussed implementing multiomics utilizing more than one biomarker and targeted therapies that have been developed using these biomarkers.
胰腺导管腺癌（PDAC）是全球癌症死亡的一个重要负担。通过早期检测该疾病并开发预测治疗反应的工具，从而选择最优化的治疗方案，与PDAC相关的糟糕预后是可以被克服的。在过去几年中，在开发有助于诊断、预后、治疗选择和监测反应的新型生物标志物方面取得了重大进展。基于血液的生物标志物为基于组织的诊断提供了一种替代方法，并且在管理PDAC方面具有巨大潜力。在这篇综述中，我们讨论了过去十年中基于血液的生物标志物在PDAC中的进展，例如DNA（突变和甲基化）、RNA、蛋白质生物标志物和循环肿瘤细胞（CTC），并且还阐明了这些生物标志物在临床实践中实际应用的各个方面。我们还讨论了利用多种生物标志物实施多组学以及使用这些生物标志物开发的靶向治疗。
